AlzeCure gets new Alzheimer’s abstract accepted

AlzeCure has announced that an abstract on NeuroRestore ACD856 – and its potential disease-modifying properties – has been accepted for presentation at the annual Clinical Trials in Alzheimer’s Conference, which is being held in San Francisco later this year.